tiprankstipranks
Trending News
More News >
Agios Pharmaceuticals (AGIO)
:AGIO
US Market
Advertisement

Agios Pharma (AGIO) Stock Forecast & Price Target

Compare
636 Followers
See the Price Targets and Ratings of:

AGIO Analyst Ratings

Moderate Buy
9Ratings
Moderate Buy
6 Buy
3 Hold
0 Sell
Based on 9 analysts giving stock ratings to
Agios
Pharma
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

AGIO Stock 12 Month Forecast

Average Price Target

$51.83
▲(47.75% Upside)
Based on 9 Wall Street analysts offering 12 month price targets for Agios Pharma in the last 3 months. The average price target is $51.83 with a high forecast of $65.00 and a low forecast of $38.00. The average price target represents a 47.75% change from the last price of $35.08.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"26":"$26","36":"$36","46":"$46","56":"$56","66":"$66"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":65,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$65.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":51.83,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$51.83</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$38.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[26,36,46,56,66],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,35,37.30769230769231,39.61538461538461,41.92307692307692,44.230769230769226,46.53846153846153,48.84615384615385,51.15384615384615,53.46153846153846,55.76923076923077,58.07692307692307,60.38461538461539,62.69230769230769,{"y":65,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,35,36.29461538461538,37.58923076923077,38.88384615384615,40.17846153846154,41.473076923076924,42.76769230769231,44.06230769230769,45.356923076923074,46.651538461538465,47.94615384615385,49.24076923076923,50.535384615384615,{"y":51.83,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,35,35.23076923076923,35.46153846153846,35.69230769230769,35.92307692307692,36.15384615384615,36.38461538461539,36.61538461538461,36.84615384615385,37.07692307692308,37.30769230769231,37.53846153846154,37.76923076923077,{"y":38,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":44.5,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.91,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.47,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.87,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.87,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.86,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.39,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.54,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.4,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.94,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.63,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.37,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$65.00Average Price Target$51.83Lowest Price Target$38.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TR | OpenAI - 4o Analyst forecast on AGIO
TR | OpenAI - 4o
TR | OpenAI - 4o
$40$38
Hold
8.32%
Upside
Reiterated
08/09/25
TD Cowen Analyst forecast on AGIO
TD Cowen
TD Cowen
Buy
Reiterated
08/05/25
Analysts Offer Insights on Healthcare Companies: Agilon Health (NYSE: AGL), Agios Pharma (NASDAQ: AGIO) and Pediatrix Medical Group (NYSE: MD)
Scotiabank Analyst forecast on AGIO
Scotiabank
Scotiabank
$65
Buy
85.29%
Upside
Reiterated
08/05/25
Scotiabank Remains a Buy on Agios Pharma (AGIO)
H.C. Wainwright Analyst forecast on AGIO
H.C. Wainwright
H.C. Wainwright
$56
Buy
59.64%
Upside
Reiterated
08/05/25
Positive Outlook for Agios Pharma Despite Recent Patient Deaths Unrelated to Pyrukynd Treatment
Leerink Partners Analyst forecast on AGIO
Leerink Partners
Leerink Partners
$45
Hold
28.28%
Upside
Reiterated
08/04/25
Analysts Offer Insights on Healthcare Companies: Agios Pharma (NASDAQ: AGIO), Madrigal Pharmaceuticals (NASDAQ: MDGL) and AbbVie (NYSE: ABBV)
RBC Capital Analyst forecast on AGIO
RBC Capital
RBC Capital
$57
Buy
62.49%
Upside
Reiterated
07/31/25
Agios Pharma (AGIO) Gets a Buy from RBC Capital
Bank of America Securities Analyst forecast on AGIO
Bank of America Securities
Bank of America Securities
$51$50
Buy
42.53%
Upside
Reiterated
07/31/25
Agios Pharma's Promising Growth: Buy Rating Backed by Strong Drug Performance and Strategic Focus
J.P. Morgan Analyst forecast on AGIO
J.P. Morgan
J.P. Morgan
Hold
Reiterated
06/25/25
Agios Pharma (AGIO) Gets a Hold from J.P. Morgan
Cantor Fitzgerald Analyst forecast on AGIO
Cantor Fitzgerald
Cantor Fitzgerald
Buy
Reiterated
05/13/25
Cantor Fitzgerald reiterates Overweight Rating on Agios Pharma (AGIO)Cantor Fitzgerald analyst Eric Schmidt reiterated an Overweight rating on Agios Pharma (NASDAQ: AGIO).
Piper Sandler Analyst forecast on AGIO
Piper Sandler
Piper Sandler
$56
Buy
59.64%
Upside
Assigned
10/23/24
Agios Pharma (AGIO) Receives a Buy from Piper Sandler
Truist Financial Analyst forecast on AGIO
Truist Financial
Truist Financial
$51
Buy
45.38%
Upside
Initiated
10/10/24
Agios Pharmaceuticals initiated with an Outperform at Raymond JamesAgios Pharmaceuticals initiated with an Outperform at Raymond James
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TR | OpenAI - 4o Analyst forecast on AGIO
TR | OpenAI - 4o
TR | OpenAI - 4o
$40$38
Hold
8.32%
Upside
Reiterated
08/09/25
TD Cowen Analyst forecast on AGIO
TD Cowen
TD Cowen
Buy
Reiterated
08/05/25
Analysts Offer Insights on Healthcare Companies: Agilon Health (NYSE: AGL), Agios Pharma (NASDAQ: AGIO) and Pediatrix Medical Group (NYSE: MD)
Scotiabank Analyst forecast on AGIO
Scotiabank
Scotiabank
$65
Buy
85.29%
Upside
Reiterated
08/05/25
Scotiabank Remains a Buy on Agios Pharma (AGIO)
H.C. Wainwright Analyst forecast on AGIO
H.C. Wainwright
H.C. Wainwright
$56
Buy
59.64%
Upside
Reiterated
08/05/25
Positive Outlook for Agios Pharma Despite Recent Patient Deaths Unrelated to Pyrukynd Treatment
Leerink Partners Analyst forecast on AGIO
Leerink Partners
Leerink Partners
$45
Hold
28.28%
Upside
Reiterated
08/04/25
Analysts Offer Insights on Healthcare Companies: Agios Pharma (NASDAQ: AGIO), Madrigal Pharmaceuticals (NASDAQ: MDGL) and AbbVie (NYSE: ABBV)
RBC Capital Analyst forecast on AGIO
RBC Capital
RBC Capital
$57
Buy
62.49%
Upside
Reiterated
07/31/25
Agios Pharma (AGIO) Gets a Buy from RBC Capital
Bank of America Securities Analyst forecast on AGIO
Bank of America Securities
Bank of America Securities
$51$50
Buy
42.53%
Upside
Reiterated
07/31/25
Agios Pharma's Promising Growth: Buy Rating Backed by Strong Drug Performance and Strategic Focus
J.P. Morgan Analyst forecast on AGIO
J.P. Morgan
J.P. Morgan
Hold
Reiterated
06/25/25
Agios Pharma (AGIO) Gets a Hold from J.P. Morgan
Cantor Fitzgerald Analyst forecast on AGIO
Cantor Fitzgerald
Cantor Fitzgerald
Buy
Reiterated
05/13/25
Cantor Fitzgerald reiterates Overweight Rating on Agios Pharma (AGIO)Cantor Fitzgerald analyst Eric Schmidt reiterated an Overweight rating on Agios Pharma (NASDAQ: AGIO).
Piper Sandler Analyst forecast on AGIO
Piper Sandler
Piper Sandler
$56
Buy
59.64%
Upside
Assigned
10/23/24
Agios Pharma (AGIO) Receives a Buy from Piper Sandler
Truist Financial Analyst forecast on AGIO
Truist Financial
Truist Financial
$51
Buy
45.38%
Upside
Initiated
10/10/24
Agios Pharmaceuticals initiated with an Outperform at Raymond JamesAgios Pharmaceuticals initiated with an Outperform at Raymond James
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Agios Pharma

1 Month
xxx
Success Rate
10/14 ratings generated profit
71%
Average Return
+2.78%
reiterated a xxx
rating 9 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 71.43% of your transactions generating a profit, with an average return of +2.78% per trade.
3 Months
xxx
Success Rate
5/10 ratings generated profit
50%
Average Return
+3.87%
assigned a xxx
rating 10 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +3.87% per trade.
1 Year
Greg HarrisonScotiabank
Success Rate
9/15 ratings generated profit
60%
Average Return
+19.58%
reiterated a buy rating 9 days ago
Copying Greg Harrison's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +19.58% per trade.
2 Years
xxx
Success Rate
9/15 ratings generated profit
60%
Average Return
+7.86%
reiterated a xxx
rating 9 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 60.00% of your transactions generating a profit, with an average return of +7.86% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AGIO Analyst Recommendation Trends

Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
7
6
7
8
7
Buy
1
2
3
6
5
Hold
4
6
9
14
14
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
12
14
19
28
26
In the current month, AGIO has received 12 Buy Ratings, 14 Hold Ratings, and 0 Sell Ratings. AGIO average Analyst price target in the past 3 months is 51.83.
Each month's total comprises the sum of three months' worth of ratings.

AGIO Financial Forecast

AGIO Earnings Forecast

Next quarter’s earnings estimate for AGIO is -$1.90 with a range of -$1.97 to -$1.71. The previous quarter’s EPS was -$1.93. AGIO beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 50.00% of the time in the same period. In the last calendar year AGIO has Outperformed its overall industry.
Next quarter’s earnings estimate for AGIO is -$1.90 with a range of -$1.97 to -$1.71. The previous quarter’s EPS was -$1.93. AGIO beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 50.00% of the time in the same period. In the last calendar year AGIO has Outperformed its overall industry.

AGIO Sales Forecast

Next quarter’s sales forecast for AGIO is $10.54M with a range of $9.41M to $12.50M. The previous quarter’s sales results were $12.46M. AGIO beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 53.62% of the time in the same period. In the last calendar year AGIO has Outperformed its overall industry.
Next quarter’s sales forecast for AGIO is $10.54M with a range of $9.41M to $12.50M. The previous quarter’s sales results were $12.46M. AGIO beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 53.62% of the time in the same period. In the last calendar year AGIO has Outperformed its overall industry.

AGIO Stock Forecast FAQ

What is AGIO’s average 12-month price target, according to analysts?
Based on analyst ratings, Agios Pharmaceuticals’s 12-month average price target is 51.83.
    What is AGIO’s upside potential, based on the analysts’ average price target?
    Agios Pharmaceuticals has 47.75% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is AGIO a Buy, Sell or Hold?
          Agios Pharmaceuticals has a consensus rating of Moderate Buy which is based on 6 buy ratings, 3 hold ratings and 0 sell ratings.
            What is Agios Pharmaceuticals’s price target?
            The average price target for Agios Pharmaceuticals is 51.83. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $65.00 ,the lowest forecast is $38.00. The average price target represents 47.75% Increase from the current price of $35.08.
              What do analysts say about Agios Pharmaceuticals?
              Agios Pharmaceuticals’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 9 Wall Streets Analysts.
                How can I buy shares of AGIO?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis